94 related articles for article (PubMed ID: 6265075)
1. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
[TBL] [Abstract][Full Text] [Related]
10. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (Cl 216,942).
Bowden GT; Garcia D; Peng YM; Alberts DS
Cancer Res; 1982 Jul; 42(7):2660-5. PubMed ID: 7083158
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
[TBL] [Abstract][Full Text] [Related]
13. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
14. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
Bukowski RM; Legha S; Saiki J; Eyre HJ; O'Bryan R
Cancer Treat Rep; 1982 Aug; 66(8):1651-2. PubMed ID: 6286120
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of dihydroxyanthracenedione.
Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
[TBL] [Abstract][Full Text] [Related]
17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
